PEDIATRICS Vol. 100 No. 4 October 1997, pp. 671-674

Bone Mineral Density in Prepubertal and in Adolescent and Young Adult Patients With the Salt-wasting Form of Congenital Adrenal Hyperplasia

Received Dec 26, 1996; accepted Feb 26, 1997.

Miquel Gussinyé^*, Antonio Carrascosa^*, Neus Potau, Manuel Enrubia^*, Enric Vicens-Calvet^*, Lourdes Ibáñez^*, and Diego Yeste^*

From the ^* Adolescent and Endocrine Unit, and  Adolescent, Endocrine, and Hormonal Units, Department of Pediatrics, Children's Hospital Vall d' Hebron, Autonomous University, Barcelona, Spain.

Objective.  To evaluate bone mineral density (BMD) in prepubertal and in adolescent and young adult patients with the salt-wasting form of congenital adrenal hyperplasia (CAH).

Design.  A relationship between bone mineral content and risk for osteoporotic fractures has been observed in adulthood. Infancy, childhood, and adolescence are critical periods for skeletal mineralization; thus, chronic diseases may impair bone mass peaking, particularly if children and adolescents are overexposed to glucocorticoids, as may occur in patients with CAH.

Lumbar L2-L4 BMD values were measured by dual x-ray absorptiometry and compared with those of 471 age- and sex-matched controls.

Patients.  Thirty-three patients with the salt-wasting form of CAH were studied. Sixteen (10 girls and 6 boys; age range, 1.5 to 8.3 years) were prepubertal and 17 (13 women and 4 men; age range, 17.1 to 28.2 years) were adolescent and young adults who had reached final height and had presented normal pubertal development and normal gonadal function thereafter. The average doses of hydrocortisone (mg/m² body surface/day) received from diagnosis in the neonatal period to BMD evaluation were 21.2 ± 2.2 and 22.3 ± 2.6, respectively.

Results.  Mean BMD Z score values were 0.16 ± 1.01 in prepubertal patients and 0.06 ± 1.02 in adolescent and young adult patients with no statistically significant differences with age- and sex-matched controls. Mean height Z score values were 0.03 ± 1.13 in prepubertal patients and 1.13 ± 0.62 in adolescent and young adult patients with significant differences between the latter and their respective age- and sex-matched controls.

Conclusion.  Long-term glucocorticoid therapy does not impair bone mass peaking in CAH patients with normal gonadal function, even though their adult height values are low.

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. F. Faienza, G. Brunetti, S. Colucci, L. Piacente, M. Ciccarelli, L. Giordani, G. C. Del Vecchio, M. D'Amore, L. Albanese, L. Cavallo, et al. Osteoclastogenesis in Children with 21-Hydroxylase Deficiency on Long-Term Glucocorticoid Therapy: The Role of Receptor Activator of Nuclear Factor-{kappa}B Ligand/Osteoprotegerin Imbalance J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2269 - 2276. [Abstract] [Full Text] [PDF]

				Z. Chakhtoura, A. Bachelot, D. Samara-Boustani, J.-C. Ruiz, B. Donadille, J. Dulon, S. Christin-Maitre, C. Bouvattier, M.-C. Raux-Demay, P. Bouchard, et al. Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency. Eur. J. Endocrinol., June 1, 2008; 158(6): 879 - 887. [Abstract] [Full Text] [PDF]

				D. P. Merke Approach to the Adult with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 653 - 660. [Abstract] [Full Text] [PDF]

				H. Falhammar, H. Filipsson, G. Holmdahl, P.-O. Janson, A. Nordenskjold, K. Hagenfeldt, and M. Thoren Fractures and Bone Mineral Density in Adult Women with 21-Hydroxylase Deficiency J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4643 - 4649. [Abstract] [Full Text] [PDF]

				M. Sciannamblo, G. Russo, D. Cuccato, G. Chiumello, and S. Mora Reduced Bone Mineral Density and Increased Bone Metabolism Rate in Young Adult Patients with 21-Hydroxylase Deficiency J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4453 - 4458. [Abstract] [Full Text] [PDF]

				J. A. King, A. B. Wisniewski, B. J. Bankowski, K. A. Carson, H. A. Zacur, and C. J. Migeon Long-Term Corticosteroid Replacement and Bone Mineral Density in Adult Women with Classical Congenital Adrenal Hyperplasia J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 865 - 869. [Abstract] [Full Text] [PDF]

				N. M. M. L. Stikkelbroeck, W. J. G. Oyen, G.-J. van der Wilt, A. R. M. M. Hermus, and B. J. Otten Normal Bone Mineral Density and Lean Body Mass, but Increased Fat Mass, in Young Adult Patients with Congenital Adrenal Hyperplasia J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1036 - 1042. [Abstract] [Full Text] [PDF]

				J. V. Zborowski, J. A. Cauley, E. O. Talbott, D. S. Guzick, and S. J. Winters Bone Mineral Density, Androgens, and the Polycystic Ovary: The Complex and Controversial Issue of Androgenic Influence in Female Bone J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3496 - 3506. [Full Text]

				P. C. White and P. W. Speiser Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency Endocr. Rev., June 1, 2000; 21(3): 245 - 291. [Abstract] [Full Text]